vimarsana.com

Latest Breaking News On - A family of randomised trials set to enrol 279 and 219 patients respectively - Page 1 : vimarsana.com

Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 - Lights up NY Times Square, NASDAQ

Tampa (Florida) [US], December 3 (ANI/PRNewswire): VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept Medical Inc. hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD Treatment: Choice of The Future' which explored the utility of Sirolimus Coated Balloon treatment in PAD. The session was chaired by Prof. Sahil Parikh, co-moderated by Prof. Edward Choke and Prof. Aloke Finn with interesting presentations by Prof. Ulf Teichgraber and Prof. Francesco Liistro. One of the highlights of the session was the follow up data of clinical outcomes of the XTOSI Trial. XTOSI (Xtreme Touch Sirolimus coated PTA balloon) is a single arm trial for Sirolimus Coated Balloon (MagicTouch PTA) investigating the clinical use and safety of the device in the treatment of infrainguinal Peripheral Arterial Disease (PAD). This prospective, premarket, non-randomized, all comers single-arm study, led by

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.